Neuronal injury biomarkers GFAP and neurofilament light chains (NfL) are associated with neurotoxicity and endothelial dysfunction in adult patients treated with antiCD19 CART cells Eugenio Galli, Anna Modoni, Luca Battistini, Monica Rossi, Gisella Guerrera, Ilaria Pansini, Alessandro Corrente, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Paolo Calabresi, Simona Sica Clinical and Experimental Medicine, 2026 Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have revolutionized the treatment of B-cell malignancies, but their use is frequently complicated by immune effector cell-associated neurotoxicity syndrome (ICANS). The underlying mechanisms include endothelial dysfunction, blood–brain barrier disruption, and neuroinflammation. Circulating biomarkers of neuronal and astroglial injury, such as neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), may provide insight into ICANS pathophysiology and serve as predictive tools. We conducted a retrospective study of 34 adult patients treated with anti-CD19 CAR-T cells for B-cell malignancies. Serum NfL and GFAP were measured at infusion (day 0) and day 7 using ultrasensitive immunoassays. Baseline GFAP and NfL levels correlated with endothelial activation markers, including mEASIX and lactate dehydrogenase, but not with demographic variables. ICANS of any grade occurred in 34% of patients, and baseline levels of both GFAP and NfL were significantly associated with ICANS development and with steroid requirement. In contrast, changes in biomarker concentrations between day 0 and day 7 were not statistically significant overall, although individual variability was observed. At day 7, elevated NfL levels correlated with laboratory evidence of disseminated intravascular coagulation (DIC), prolonged clotting time, and C-reactive protein elevation. GFAP elevation was also linked to coagulopathy, particularly prolonged clotting time. Baseline serum levels of GFAP and NfL predict the risk of ICANS and the need for corticosteroid intervention in CAR-T-treated adults, supporting their role as biomarkers of pre-existing neuronal susceptibility. Furthermore, their association with coagulation abnormalities underscores the interplay between neurotoxicity, endothelial stress, and systemic inflammation. These findings highlight the potential clinical utility of integrating GFAP and NfL into multimodal biomarker panels to improve risk stratification and management of CAR-T neurotoxicity.
Kinase inhibition rewires the HLA-I immunopeptidome in chronic myeloid leukemia Veronica Venafra, Maria Wahle, Giorgia Massacci, Valeria Bica, Patrizia Chiusolo, Dimitrios Mougiakakos, Martin Boettcher, Thomas Fischer, Livia Perfetto, Matthias Mann, Francesca Sacco Iscience, 2026 Immunotherapy offers promising opportunities to improve immune-mediated control of chronic myeloid leukemia (CML), but its success depends on identifying antigens uniquely associated with CML. Protein kinases regulate signaling and protein turnover, influencing which peptides are presented on HLA molecules. Although earlier studies suggested that kinase inhibition can alter immune recognition of cancer cells, the underlying mechanisms remain unclear. In this study, we investigated whether targeting key kinases could reshape the CML immunopeptidome. The pharmacological inhibition of SFK, JNK, and BCR-ABL caused broad remodeling of antigen presentation, affecting the display of 4,000 HLA-I ligands. By integrating immunopeptidomics, phospho-immunopeptidomics, and proteomics, we identified three complementary mechanisms regulating antigen display. Comparing benign hematologic tissues with CML samples revealed about 90 CML-specific peptides that became more prominent after SFK or JNK inhibition. Overall, this work provides a quantitative, multi-omic framework to rationally combine kinase inhibitors with immunotherapy to boost antigen visibility and antileukemic immunity.
High Frequency of Germline ATM Variants in Familial Philadelphia-Negative Myeloproliferative Neoplasms Francesco Ramundo, Tanja Malara, Luca Di Marino, Roberto Maggi, Silvia Betti, Monica Rossi, Gessica Minnella, Angelo Minucci, Maria De Bonis, Roberto Bertozzi, Elena Rossi, Simona Sica, Valerio De Stefano, Patrizia Chiusolo American Journal of Hematology, 2026 Familial Philadelphia-negative myeloproliferative neoplasms (MPNs) represent a recognized subset of these clonal hematopoietic disorders, accounting for approximately 7%–8% of all MPN cases [1]. Population-based studies have demonstrated a high risk of MPNs among first-degree relatives of affected individuals, particularly in families with multiple affected members or in relatives of younger patients [2, 3]. Notably, familial and sporadic cases show no significant differences in clinical phenotype, disease complications, or risk of progression, suggesting that familial MPNs share the same disease biology and prognosis as their sporadic counterparts [4]. However, as in other familial cancers, second-generation individuals experience earlier disease onset or more aggressive phenotypes [5]. In addition, the spectrum of somatic mutations closely mirrors that of sporadic MPNs, with JAK2 V617F being the most common acquired driver mutation. Nevertheless, discordant somatic mutations are frequently observed among related individuals, suggesting that while shared germline factors may confer susceptibility to clonal hematopoiesis, the acquisition of specific driver mutations occurs stochastically and independently [6]. In this context, we conducted a retrospective, single-center study aimed at identifying germline variants (GVs) in individuals with familial MPNs through next-generation sequencing (NGS). We included all patients diagnosed with MPNs at Fondazione Policlinico Gemelli IRCCS between 1976 and 2024 who had at least one relative affected by an MPN. All diagnoses were confirmed according to WHO 2022/ICC criteria [7, 8]. DNA was extracted from cryopreserved peripheral blood samples, and clinical data were retrieved from medical records. All participants provided written informed consent per the Declaration of Helsinki. The study was conducted under protocol NCT06923670 (ClinicalTrials.gov). A custom enrichment panel targeting 69 genes (Illumina, San Diego, CA), selected based on established evidence for hereditary cancer syndromes, was designed using Illumina Design Studio. The full gene list is provided in Table S1. Germline variants were classified into 5 categories according to American College of Medical Genetics and Genomics guidelines: pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), likely benign, and benign [9]. The SIFT (Sorting Intolerant From Tolerant) tool was used to predict the functional impact of amino acid substitutions, with variants scoring < 0.05 considered deleterious [10]. Among a cohort of 1515 MPN patients, 107 (7.1%) met the inclusion criteria and were included in the analysis. The median age at diagnosis was 47.5 years (range 1–82 years), with a predominance of female patients (56.1%). In 57.9% of cases, the proband had at least one first-degree relative with a myeloid neoplasm; 28.9% had affected second-degree relatives, and 13.1% had affected third-degree relatives. In 16 cases (14.9%), more than one relative was affected by a myeloid neoplasm: two affected relatives in 12 cases and three affected relatives in 4 cases. The most common MPN subtype was Essential Thrombocythemia (ET, 49.5%), and the majority of patients (72.9%) harbored the JAK2 V617F mutation. Complete follow-up data were available for 105 patients. Among these, 100 (95.2%) received antithrombotic therapy, 69 (65.7%) underwent at least one cytoreductive treatment, and 30 (28.6%) experienced a thrombotic event. Twenty-eight (28.9%) of the 97 patients with ET, polycythemia vera (PV), pre–primary myelofibrosis (pre-PMF), or myeloproliferative neoplasm unclassifiable (MPN-U) progressed to overt-PMF (patients with overt-PMF at diagnosis were not included), and three (2.9%) of the entire cohort developed acute leukemia. At the time of analysis, 13 patients (12.4%) had undergone allogeneic stem cell transplantation, 8 (7.6%) died, and 16 (15.2%) were lost to follow-up. Notably, 22 patients (20.9%) had a history of another malignancy, including three (2.9%) who developed an additional hematologic neoplasm (two chronic lymphocytic leukemia [CLL] and one chronic myeloid leukemia [CML]). Demographic and clinical characteristics of the cohort are summarized in Table 1. A total of 106 GVs were identified across 45 distinct genes included in our panel. Sixty-eight patients (63.6%) carried at least one GV (benign and likely benign GVs were excluded from the analysis): 38.3% had a single variant, 16.8% two, 6.5% three, and 1.9% four variants (Figure 1A). Most patients (46.7%) carried only VUS, while 9.3% harbored a LP variant, and 7.5% carried a pathogenic variant. JAK2 V617F was the most frequent somatic mutation in patients with GVs, detected in 76.5% of these individuals. There was no significant difference in GVs prevalence between JAK2-mutated and wild-type patients (χ2 = 0.35, p = 0.55), and GVs presence was independent of MPN subtype (Fisher's exact test p = 0.65). However, a significant difference in JAK2 V617F variant allele frequency (VAF) was observed between patients with and without GVs (Wilcoxon rank-sum test p = 0.016), with a higher median VAF in patients harboring GVs (39% vs. 14%). Thirty-eight patients (35.5%) in the cohort were directly related, forming 19 family pairs. Among these, 11 pairs (57.9%) harbored the same driver mutation—JAK2 V617F in 9 pairs (47.4%) and MPL S505N in 2 pairs (10.5%)—while only 8 pairs (42.1%) presented with concordant clinical phenotypes, all diagnosed as ET. In addition, six other individuals with MPN (5.6%) had a family member affected by a different myeloid malignancy (4 with acute myeloid leukemia, 1 with CML, and 1 with chronic myelomonocytic leukemia), all followed at our institution. A sub-analysis was therefore conducted on 25 pairs (50 individuals) of related subjects with available genetic material. The median age at diagnosis in the second generation was significantly lower than in the first generation (43 years vs. 61 years, p = 0.006). Among these 50 individuals, 36 (72.0%) carried at least one GV, most of which (n = 33, 66.0%) were classified as VUS. Nine (18%) presented a P/LP variant and in 12 pairs (48%), both individuals shared at least one identical GV. Figure S1. ATM was the most frequently mutated gene, with GVs identified in 12 patients (11.2%) (Figure 1B). Detailed information on the identified ATM variants is provided in Table 2. Among these 12 patients, 8 were from 4 familial pairs, and in each case, both members of the pair carried the identical mutation; therefore, the incidence of the ATM GVs among families was 9.1% (8 of 88 families). One individual was found to harbor two distinct ATM GVs. ATM variants were classified as pathogenic in 3 patients (3.1%), LP in 1 patient (1.0%), and VUS in 8 patients (8.2%). However, when evaluated using the SIFT algorithm, 5 of the 9 VUS were predicted to be deleterious (SIFT score < 0.05). Patients with identified ATM variants were further investigated to confirm the germline origin of the mutation. Specifically, NGS analysis was performed on DNA samples obtained from saliva, which confirmed the germline origin of the mutation. These patients were subsequently also examined via WES, which corroborated the variants identified by the NGS panel and did not reveal any additional variants associated with hematopoietic abnormalities of note. In this single-center study, approximately 7% of MPN cases met criteria for familial disease, consistent with prior reports [1]. We confirmed anticipation, with second-generation individuals showing earlier disease onset. JAK2 V617F was the most frequent somatic driver mutation, and patients harboring GVs exhibited higher median VAFs, suggesting that inherited alterations may facilitate clonal expansion. In familial pairs, concordance of phenotype and driver mutation was uncommon, whereas nearly half shared at least one GV, highlighting the role of inherited factors beyond canonical drivers in familial MPN predisposition. ATM emerged as the most frequently mutated germline gene. ATM, located on chromosome 11, encodes a serine/threonine kinase essential for DNA damage response and oxidative stress regulation, coordinating cell-cycle arrest, apoptosis, and metabolic reprogramming through TP53 activation to preserve genomic integrity [12]. The contribution of ATM to cancer predisposition is well established in patients with ataxia–telangiectasia, who exhibit a markedly increased risk of early-onset malignancies, predominantly hematologic [13]. Moreover, several studies have reported germline ATM variants in familial hematologic neoplasms—including CLL and myeloid diseases as well as in hereditary solid tumors [14-18]. An Italian study recently reported P/LP germline mutations in approximately 7% of individuals with familial or early-onset (< 27 years) MPNs, a frequency lower than that observed in our cohort (18.4%) [19]. This difference likely mirrors the fact that our study population consisted solely of individuals with affected family members. Notably, 2.2% of subjects in this study harbored CHEK2 mutations, which interact with ATM and have been associated with an increased risk of second malignancies and leukemic transformation [19]; in our cohort, only one subject (0.9%) carried a CHEK2 LP variant. Beyond the ATM GVs, several identified variants affect genes involved in DNA interstrand cross-link repair. Biallelic mutations in these genes cause Fanconi anemia, while heterozygous variants increase cancer susceptibility [20]. We identified 18 GVs across 9 genes. BRCA2 and FANCD2 were most frequently affected [3 (2.8%) patients each with VUS] while 6 (5.6%) subjects carried P/LP variants in FANCA, FANCE, FANCL, and XRCC2. Our findings support a potential role for ATM, along with other genes predominantly involved in DNA repair pathways, as predisposing factors in familial MPNs, underscoring the critical importance of genomic stability in cancer predisposition. A limitation of our study is the use of a targeted gene panel; however, WES performed in the subset of patients with ATM mutations did not reveal any additional pathogenic variants. Family history should be an integral component of the diagnostic workup for MPNs, and further studies are needed to clarify germline contributions to disease susceptibility, with potential implications for therapeutic strategies and donor selection in patients undergoing hematopoietic stem cell transplantation. P.C., S.S., F.R., T.M., and L.D.M. conceived and designed the study. P.C., F.R., L.D.M., R.M., and S.B. collected the data. T.M., M.R., and G.M. performed the NGS analyses, while A.M., M.D.B., and R.B. conducted the WES analysis. P.C. and F.R. wrote the manuscript. E.R., S.S., V.D.S., and P.C. critically reviewed and revised the manuscript for important intellectual content. This monocentric study serves as the pilot phase of a larger multicenter project titled “Prevalence of Germline Gene Mutations in Patients with Myeloproliferative Neoplasms and a Family History of Hematological Neoplasms.” This research is conducted under the patronage of GIMEMA (Italian Group of Adult Hematological Diseases). The authors acknowledge the support of the “Centro di Ricerca sulle Cellule Staminali Emopoietiche e le Terapie Cellulari, Università Cattolica del Sacro Cuore, Roma” research funding. We sincerely thank Prof. Paola Guglielmelli for her valuable advice. This study was conducted with the support of the research funding from the “Centro di Ricerca sulle Cellule Staminali Emopoietiche e le Terapie Cellulari, Università Cattolica del Sacro Cuore, Roma”. The data supporting the findings of this study were collected as part of a registered clinical trial (ClinicalTrials.gov Identifier: NCT06923670). The authors declare no conflicts of interest. Original data will be made available upon reasonable request to the corresponding author, in accordance with institutional and ethical guidelines. The raw sequencing reads have been deposited in the NCBI Sequence Read Archive (SRA; accession no. SRP631076) and BioProject (accession no. PRJNA1312845). Table S1: List of genes included in NGS-panel and their cellular function. Figure S1: Distribution of germline variants per gene identified among 25 pairs of related individuals. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
PTCy or ATG for Matched Transplantation in Myelofibrosis Patrizia Chiusolo, Andrea Bacigalupo, Rachel Salit, Thomas Schroeder, Maria Chiara Finazzi, Carmelo Gurnari, Simona Pagliuca, Judith Metzdorf, Christina Rautenberg, Marie Robin, Marie‐Thérèse Rubio, Jaroslaw Maciejewski, Uday Popat, Alessandro Rambaldi, Hans Christian Reinhardt, Bart Scott, Nicolaus Kröger, Nico Gagelmann American Journal of Hematology, 2026 Allogeneic hematopoietic stem cell transplantation remains the only curative therapy, yet outcomes are tempered by graft failure, relapse, infectious complications, and graft-versus-host disease (GVHD) [1]. Two approaches for GVHD prophylaxis dominate: anti-thymocyte or anti-T-lymphocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy). ATG provides broad in vivo T-cell depletion and reduces GVHD risk and has been shown to improve outcomes in all donor settings [2]. PTCy, primarily used in the haploidentical setting, acts post-transplant to selectively eliminate proliferating alloreactive T cells while preserving regulatory and memory populations, potentially mitigating GVHD while supporting immune reconstitution [3]. Both strategies have shown efficacy [2, 4-7], yet their relative impact in myelofibrosis in the matched donor setting—a disease with unique transplant dynamics—remains unclear. This study aims to evaluate outcomes of HLA-matched transplantation in MF using either ATG or PTCy. This was a retrospective, non-randomized comparison in patients undergoing transplantation for myelofibrosis between 2010 and 2024. Additional GVHD prophylaxis in both arms consisted of cyclosporine A together with mycophenolate mofetil or methotrexate, depending on center standards. Patients with accelerated-phase or blast-phase MF were excluded [8]. Dose for PTCy was 50 mg/kg/day on 2 days after transplant. Patients receiving ATG included two different brands: Thymoglobulin (Sanofi, France) 3.5 mg/kg/day on 2 days before transplantation or Grafalon (Neovii, Germany) 30 mg/kg/day for matched siblings and 60 mg/kg/day for matched unrelated donors on 3 days before transplantation. To account for selection bias and potential confounding factors between groups in outcome comparisons, we employed a weighted propensity score analysis to balance baseline characteristics between patients who received ATG versus PTCY. The propensity score model was generated using the inverse probability of treatment weighting (IPTW) approach, where each patient was weighted by the inverse probability of being in the ATG or PTCY group. Weighted Cox proportional hazards models were used to assess survival outcomes, hazard ratios (wHRs), and Fine-Gray regression was used for endpoints with competing risks. A total of 539 patients were included, with 427 receiving ATG and 112 PTCy (Supplemental Table 1), and the median age was comparable between groups (58 vs. 60 years, p = 0.21). Donor type showed a trend toward more matched related donors in the PTCy group compared with ATG (38% vs. 28%, p = 0.06). Conditioning intensity differed significantly between groups: reduced-intensity regimens were predominant in the ATG group (79%), whereas nearly half of patients in the PTCy group received higher-intensity conditioning (47%; p < 0.001). Median follow-up was 4.8 years for the ATG group and 3.7 years for the PTCy group (p = 0.12). We first performed an unadjusted univariate comparison of ATG versus PTCy (Table 1). In terms of engraftment, neutrophil recovery occurred significantly earlier in patients receiving ATG compared with those given PTCy (median 14 vs. 23 days, p < 0.001; Figure 1) and primary graft failure was more frequent after PTCy (7% vs. 1%: p < 0.001). Cumulative incidence of platelet engraftment was 88% for ATG versus 73% for PTCy (p < 0.001). Relapse incidence at 4 years was lower in the ATG group (14%) compared with PTCy (33%; p < 0.001), and non-relapse mortality at 4 years was similar between groups (24% vs. 26%; p = 0.53). Overall survival at 4 years showed a trend in favor of ATG (71% vs. 64%; p = 0.08). In terms of GVHD (Figure 2), chronic GVHD was significantly more common in the ATG cohort, affecting 50% at 4 years compared with 23% in the PTCy cohort (p < 0.001). Furthermore, the severity of chronic GVHD was significantly different between the groups, with moderate–severe chronic GVHD occurring in 27% for ATG versus 10% for PTCy (p = 0.02). Rates of acute GVHD by day 180 were comparable (30% vs. 27%; p = 0.40), with severe acute GVHD grade III–IV being numerically higher for ATG (10%) versus PTCy (5%). GRFS at 4 years was 42% in the ATG group and 37% in the PTCy group, with no significant difference (p = 0.14). We next performed matched analyses. Here, relapse incidence remained higher in patients receiving PTCy versus ATG (33% vs. 20%; p = 0.15), while GRFS was comparable between groups (37% with PTCy vs. 31% with ATG, p = 0.37). In multivariable models of matched cohorts, PTCy was associated with significantly lower risk of chronic GVHD compared with ATG (HR 0.60; p = 0.001), with a trend for increased risk of relapse with PTCy (HR 1.41; p = 0.2). For GRFS, we observed no significant difference (HR 0.94; p = 0.7). Together, these findings indicate that in the propensity score-matched cohort, no differential impact on GRFS was detected for either prophylaxis strategy, with nuanced results for GRFS components indicating higher risk for relapse but lower risk for chronic GVHD with PTCy compared with ATG (Supporting Information). GVHD remains a major obstacle in allogeneic transplants for myelofibrosis: in a recent study, acute GvHD grade III–IV was reported to occur in 22% of MF patients, with a higher rate of liver involvement [9]. ATG has been shown to reduce GVHD in patients with hematologic malignancies and to increase the proportion of recipients free of immunosuppressive therapy at 2 years [2, 7]. Engraftment is another key issue for MF patients following an allogeneic transplantation, given that these patients tend to be at onset higher risk for late engraftment, graft failure, or poor graft function [10, 11]. Identifying the right GVHD prophylaxis therefore becomes crucial for these patients receiving matched transplants, where graft failure rates would be expected to be low [12]. Our findings of delayed engraftment and higher graft failure rates with PTCy are in line with recent studies [6]. Future studies should investigate whether optimization of PTCy dose or a combination of ATG and PTCy can mitigate graft failure risk without compromising GVHD protection. Relapse also remains a relevant problem overall after transplant, and specifically in MF patients [13]. One of the key questions in the transplant field is whether GVHD protection with PTCy dissociates from a graft-versus-leukemia effect. While some studies suggested no increased relapse with PTCy [14, 15], others have shown in the particular setting of MF that there is a nuanced association between GVHD and relapse [9, 16]. The present study is underpowered to investigate the potential association of relapse and GVHD in the PTCy setting in a robust fashion. Of note, one particular difference between MF and other myeloid diseases is the type of relapse and its assessment (molecular vs. hematological vs. both) [17]. One reason for higher relapse in our group could be due to close post-transplant follow-up and clinical evaluation while most registry studies have no access to reliable relapse assessment, which could impact relapse rate interpretations. However, the results seen for PTCy are closely correlated with most recent reports [6]. This study has inherent limitations related to its retrospective, non-randomized design, which precludes full control for unmeasured confounders. In addition, the use of PTCy versus ATG was largely center-specific rather than evenly distributed across contributing institutions, introducing potential institutional practice effects that cannot be entirely excluded despite broadly homogeneous transplant approaches for myelofibrosis across centers. Detailed, standardized data on the timing and intensity of post-transplant immunosuppression tapering and discontinuation were not available, precluding analysis of potential differences between the PTCy and ATG groups. Given the observed trade-off between graft-versus-host disease and relapse in this study, the impact of prophylaxis duration on these outcomes warrants prospective investigation. Finally, a cautious analytic approach was adopted: because detailed post-transplant monitoring data (including transfusion requirements and relapse-directed therapies) were not consistently available, and other modalities such as chimerism assessment were not uniformly performed across the cohort and are technology-dependent, these variables were not included in the analysis to limit heterogeneity and reduce the risk of biased or overinterpreted findings. Future studies should assess the potential for early molecular targeted intervention to reduce incidence or burden of relapse, particularly in the PTCy setting [18, 19]. In conclusion, PTCy was associated with reduced chronic GVHD but increased risk of relapse and graft failure in myelofibrosis undergoing HLA-matched allogeneic transplantation, with similar GRFS and overall survival compared with ATG. The authors have nothing to report. Has been obtained by each center. Has been obtained by each center. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Data S1: ajh70244-sup-0001-Supinfo.docx. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Systemic Inflammation and CAR-T Specific Toxicities as Major Drivers of Nonrelapse Mortality: Analysis from the Italian Prospective Observational CART-SIE Study Angelica Barone, Federico Stella, Silva Ljevar, Beatrice Casadei, Stefania Bramanti, Patrizia Chiusolo, Alice Di Rocco, Maria Chiara Tisi, Ilaria Cutini, Piera Angelillo, Massimo Martino, Maurizio Musso, Mirko Farina, Martina Pennisi, Anna Maria Barbui, Roberto Freilone, Jacopo Olivieri, Giovanni Grillo, Pellegrino Musto, Francesco Saraceni, Mauro Krampera, Lucia Brunello, Alessia Castellino, Simone Ragaini, Luca Arcaini, Annalisa Chiappella, Anna Guidetti, Anna Dodero, Rosalba Miceli, Pierluigi Zinzani, Paolo Corradini Transplantation and Cellular Therapy, 2026 BACKGROUND: Chimeric antigen receptor (CAR)-T cell therapy has revolutionized outcomes in relapsed/refractory lymphomas, yet nonrelapse mortality (NRM) has emerged as a notable concern, with older age and infections identified as major determinants of NRM in real-life studies. OBJECTIVE: The aim of the present study was to describe the rate and causes of NRM after CAR-T cells and identify risk factors. STUDY DESIGN: Within the framework of the prospective, multicenter, observational CART‑SIE study, we analyzed causes and determinants of NRM in a large real-world cohort of lymphoma patients receiving CAR‑T cells from 2019 to 2025. Associations between NRM and clinical or biological factors were assessed using Fine and Gray subdistribution hazard models. RESULTS: From 2019 to 2025, 1132 patients were enrolled in the CART-SIE Study; among those, 932 were evaluable for outcomes, with a median follow-up of 17.8 months (IQR 6.3-25.4). In this cohort, 305 deaths were observed, mainly occurring after disease progression (n = 258); overall, 47 deaths were solely attributable to NRM (5%), either early (≤28 days, 40.4%), late (29-90 days, 23.4%) or very late (>90 days, 36.2%). The 1- and 2-year cumulative incidence of NRM were 5.5% and 8.8%. Infections were the leading cause (51%), followed by CAR-T acute toxicities (CRS, ICANS, and HLH/MAS; 30%), and secondary malignancies (11%). In univariable analysis, age > 60 gt; 60 years, diabetes, atrial fibrillation, high CAR-HEMATOTOX score, elevated ferritin, baseline cytopenias, CRS grade ≥3, any-grade or grade ≥3 ICANS and infectious events were risk factors for NRM. Multivariable models revealed that, among pre-infusion factors, only high ferritin levels (HR 3.23, 95% CI: 1.37-7.62, P = .007) and diabetes (HR 3.93, 95% CI: 1.28-12.1, P = .017) independently predicted NRM, while only severe CRS, ICANS, and infections remained strong post-infusion predictors. CONCLUSIONS: These findings emphasize the role of host-related factors and inflammation in shaping CAR-T outcomes. Optimized patient selection, rigorous management of acute toxicities, tailored infectious prophylaxis and long-term oncologic surveillance are essential components of long-term survivorship care, aiming to mitigate NRM and sustain long-term benefits of CAR-T cells. Clinical trial registration ClinicalTrials.gov ID: NCT06339255.
Organ-specific local cytokine release syndrome after anti-CD19 CAR-T therapy with salivary gland involvement: a case report, literature review, and a diagnostic alert for tocilizumab-associated cervical swelling Roberto Maggi, Enrico Federico Ricciuti, Eugenio Galli, Federica Sorà, Antonella Fiorita, Simona Sica, Patrizia Chiusolo Annals of Hematology, 2026 Background. Cytokine release syndrome (CRS) is the most frequent toxicity after chimeric antigen receptor T-cell (CAR-T) therapy and typically presents as a systemic inflammatory syndrome. In recent years, a localized form of CRS (L-CRS), most commonly involving the craniocervical region, has been increasingly recognized. L-CRS may occur with or without overt local tumor involvement and can progress to airway impairment, requiring prompt recognition and treatment. Case presentation. We report two cases of patients with refractory diffuse large B-cell lymphoma (DLBCL) treated with anti-CD19 CAR-T therapy who developed abrupt, painful bilateral parotid and/or submandibular gland swelling (left predominance) early after infusion, following systemic CRS treated with tocilizumab. Infectious, obstructive, and autoimmune causes were excluded; ultrasound findings were compatible with inflammatory glandular changes. Given rapid progression and concern for airway patency, corticosteroids were administered with prompt clinical resolution. Literature review and diagnostic alert. We provide an overview of published L-CRS with craniocervical presentations (Table 1). Similar acute swelling temporally related to tocilizumab has been reported in other settings. In such cases, differential diagnostics of L-CRS vs. a tocilizumab-associated infusion-related/hypersensitivity reaction needs to be carried out. Conclusion. L-CRS is a clinically relevant and potentially severe complication of CAR-T therapy that may involve salivary glands even without cervical tumor burden. Clinicians should also consider drug-related reactions, particularly when cervical swelling occurs shortly after tocilizumab administration.
Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study Nicola Polverelli, Annalisa Chiappella, Cristiana Carniti, Pierluigi Zinzani, Maurizio Musso, Maria Chiara Tisi, Fabio Ciceri, Ilaria Cutini, Armando Santoro, Patrizia Chiusolo, Anna Maria Barbui, Mirko Farina, Livia Donzelli, Lucia Brunello, Massimo Martino, Mauro Krampera, Alessia Castellino, Giovanni Grillo, Barbara Botto, Jacopo Olivieri, Michele Clerico, Pellegrino Musto, Attilio Olivieri, Antonio Bianchessi, Irene Defrancesco, Giulia Losi, Caterina Zerbi, Gianluca Martini, Elisa Roncoroni, Manuel Gotti, Maria Grazia Benevento, Alessia Taurino, Anna Fedina, Paolo Corradini, Luca Arcaini Hemasphere, 2026 Hepatitis B virus (HBV) remains one of the most common chronic viral infections worldwide, with an estimated 257 million people affected. HBV-positive (HBV+), defined by the presence of anti-HBc antibodies without detectable HBV-DNA (occult hepatitis B virus infection, OBI), is particularly relevant in immunocompromised patients. In the setting of hematologic malignancies, HBV reactivation can occur during or after chemotherapy, immunotherapy, or stem cell transplantation, leading to potentially life-threatening complications.1, 2 Therefore, prophylactic antiviral therapy is generally recommended in these clinical scenarios, with recent updates regarding the choice of agent and duration of treatment.3 T-cell engagers such as bispecific antibodies and chimeric antigen receptor T (CAR-T) cells are becoming pivotal in the treatment of several hematological disorders; in particular, CAR-T-cell therapy has emerged as a breakthrough treatment for relapsed or refractory lymphomas, including large B-cell lymphomas (LBCLs), mantle cell lymphoma (MCL), follicular lymphoma, and other neoplasms.4 However, limited data exist regarding the safety and efficacy of such therapies in the context of HBV carriers.5-8 In a recent report on 99 multiple myeloma (MM) patients treated with BCMA-targeted CAR-T-cell therapy, 7 of those with chronic infection and 43 with resolved HBV infection, 4 patients (1 with chronic and 3 with resolved infection) experienced HBV reactivation, resulting in 2 cases of severe hepatitis and 1 HBV-related death, despite use of specific antiviral therapy.9 To the best of our knowledge, only two OBI patients treated with CD19-targeted CAR-T cells have been reported so far.10 The CART-SIE study, an ongoing multicenter prospective observational study collecting data on all consecutive lymphoma patients treated with commercial CAR-T cells in Italy, offers a unique opportunity to explore this question in a large, real-world population.11 Thus, we retrospectively analyzed 1124 consecutive patients treated with anti-CD19 commercially available CAR-T-cell therapy for lymphoma within the CART-SIE study. Patients with active HBV infection were excluded according to Italian regulatory requirements. Patients with evidence of prior HBV exposure (anti-HBc positive, HBV-DNA negative; HBV+) were compared with HBV serologically negative patients (HBV−). All HBV+ patients received antiviral prophylaxis before and after CAR-T-cell therapy, mostly with lamivudine (>90%). Median follow-up, calculated by reverse Kaplan–Meier method,12 was 16.5 months (95% CI, 13.2–17.8). Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included overall response rate (ORR), complete response (CR) rate, relapse incidence, and CAR-T-cell–related toxicities, including cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), immune effector cell–associated hematotoxicity (ICAHT), infections, and secondary malignancies. Survival outcomes were estimated using the Kaplan–Meier method and Cox proportional hazards regression models. Associations between OBI status and patient- and disease-related characteristics, as well as categorical outcomes—including response rates, relapse incidence, and treatment-related toxicities—were assessed using the t test for continuous variables and the chi-square test for categorical variables, as appropriate. Multivariable logistic regression models were used to identify factors associated with treatment-related toxicities and HBV positivity. For CAR-T-cell kinetic analyses, between-group comparisons were performed using two-sided Mann–Whitney U tests, and results were reported as medians with interquartile ranges (Q1–Q3). A two-sided P-value < 0.05 was considered statistically significant. Baseline characteristics were largely balanced between HBV+ (n = 114) and HBV− patients (n = 1010), except that HBV+ patients were older (median 62.2 vs. 57.2 years; P < 0.001) and had a higher prevalence of diffuse large B-cell lymphoma (DLBCL; 77.2% vs. 61.9%; P = 0.001). Table 1 details the patients' characteristics by HBV serostatus. Response rates at Day 30 were comparable between the two groups (ORR 79.3% vs. 80.3%, with CR rates of 56.1% in HBV− vs. 57.0% in HBV+ patients, P = 0.913). Similar results were observed at Day 90 (ORR 72.2% vs. 72.2%, with CR rates of 63.3% vs. 60.2%; P = 0.791). Relapse rates were slightly higher in the HBV+ cohort (50.9% vs. 42.0%, P = 0.073); however, when analyzed in a time-dependent manner, long-term outcomes were comparable between groups. The 12- and 36-month OS rates were 70.8% (95% CI, 67.4–73.9) and 53.8% (95% CI, 48.8–58.6) in HBV− patients, compared with 64.0% (95% CI, 52.9–73.2) and 52.6% (95% CI, 40.7–63.2) in HBV+ patients (P = 0.239). The corresponding 12- and 36-month PFS rates were 50.6% (95% CI, 47.1–53.9) and 42.0% (95% CI, 37.7–46.2) in HBV− patients versus 43.2% (95% CI, 33.0–52.9) and 35.8% (95% CI, 25.8–45.9) in HBV+ patients, respectively (P = 0.163) (Figure 1A,B). After adjustment for factors known to be associated with outcomes (age, sex, lymphoma histotype [DLBCL vs. other types], number of prior therapies, previous autologous stem cell transplant, and use of bridging therapy), multivariable analyses confirmed that HBV positivity did not significantly affect either OS (HR 1.12, 95% CI, 0.80–1.57, P = 0.497) or PFS (HR 1.15, 95% CI, 0.88–1.51, P = 0.304). Regarding toxicities, no cases of HBV reactivation were detected. Notably, CRS occurred less frequently in HBV+ patients (81.6% vs. 88.4%, P = 0.049), a finding that remained significant after adjustment for age, diagnosis, and CAR-T-cell product (odds ratio 0.55; 95% CI, 0.32–0.95, P = 0.033). In contrast, the incidence of ICANS was similar between HBV– and HBV+ patients (26.8% vs. 28.1%, P = 0.824), although HBV+ patients more frequently experienced milder forms (Grade I: 56.2% vs. 39.2%, P = 0.043). Rates of ICAHT (24.6% vs. 18.4%, P = 0.165), secondary malignancies (3.9% vs. 6.1%, P = 0.219), and infections (11.5% vs. 9.6%, P = 0.642) were comparable between the HBV– and HBV+ groups, respectively. Given the established association between early CAR-T-cell expansion and the risk/severity of CRS and ICANS,13 we evaluated expansion kinetics to assess whether HBV serostatus and/or antiviral prophylaxis could modulate in vivo CAR-T-cell activity. No statistically significant differences were observed between HBV+ and HBV− patients with respect to time to maximal expansion (TMAX; HBV+ n = 38: 10.00 days [7.00–10.00] vs. HBV− n = 306: 10.00 [7.00–14.00]; P = 0.233), Day 10 expansion (C10; HBV+ n = 24: 13.37 [6.07–71.02] vs. HBV− n = 172: 24.45 [9.20–61.91]; P = 0.483), overall expansion during the first 30 days post-infusion (area under curve [AUC]0–30; HBV+ n = 39: 324.70 [164.90–1137.79] vs. HBV− n = 316: 436.80 [191.76–1169.87]; P = 0.749), or peak of expansion (CMAX; HBV+ n = 39: 39.67 [13.93–127.88] vs. HBV− n = 317: 44.74 [16.18–109.24]; P = 0.947). Overall, HBV serostatus was not associated with measurable differences in the magnitude or timing of early CAR-T-cell expansion within the first 30 days post-infusion (Figure S1). In this large real-world analysis from the CART-SIE study, we show that occult HBV infection does not negatively impact efficacy or safety outcomes of anti-CD19 CAR-T-cell therapy in lymphoma patients when appropriate antiviral prophylaxis is adopted. To our knowledge, this represents the largest dataset addressing this clinically relevant issue in the CAR-T-cell setting. Despite HBV+ patients being older and more frequently affected by DLBCL, both unfavorable prognostic features,14, 15 early response rates and long-term outcomes were comparable between HBV+ and HBV− cohorts. Neither OS nor PFS differed significantly in the long term, and multivariable analyses confirmed that HBV serostatus was not independently associated with inferior outcomes. Although relapse incidence was numerically higher among HBV+ patients, this did not translate into worse survival, suggesting no clinically meaningful impact on long-term disease control. From a safety standpoint, no cases of HBV reactivation were observed, underscoring the effectiveness of systematic antiviral prophylaxis in this setting.16 This finding is particularly reassuring in light of previous reports describing severe HBV reactivation following T-cell–engaging therapies, in which prophylactic antiviral treatment was less consistently adopted.17 Notably, despite recent recommendations favoring entecavir or tenofovir for HBV prophylaxis, no reactivation events were observed in our cohort, in which lamivudine was widely used.18 In the context of undetectable HBV-DNA at baseline, the use of a low–genetic barrier but well-tolerated agent such as lamivudine appears effective in preventing HBV reactivation. Nevertheless, given the limited prospective evidence, further studies are warranted to better define the optimal prophylactic strategy in this setting.3 Overall, CAR-T-cell–related toxicities were comparable between groups. Interestingly, HBV+ patients experienced a lower incidence of CRS, a signal that remained significant after adjustment for relevant confounders. Additionally, milder forms of ICANS were documented in the HBV+ population. Notably, this toxicity profile was not associated with differences in early CAR-T-cell expansion kinetics, which were comparable between HBV+ and HBV− patients. While the biological basis of these observations remains speculative, they may reflect immunomodulatory effects related to viral exposure or antiviral therapy19, 20; however, the lack of correlative immunological data precludes definitive conclusions. Accordingly, these findings should be interpreted with caution and considered hypothesis-generating. Limitations include the retrospective nature of the analysis and the absence of extended longitudinal HBV-DNA and lymphoid population monitoring. Nevertheless, the large sample size, multicenter prospective data collection, and real-world setting strengthen the robustness and generalizability of our findings. In conclusion, OBI status (anti-HBc positive, HBV-DNA negative) does not appear to adversely affect clinical outcomes or toxicity profiles in lymphoma patients undergoing CAR-T-cell therapy. With appropriate antiviral prophylaxis, HBV positivity should not be considered a contraindication to CAR-T-cell treatment. We are deeply grateful to the patients who participated in this study and their caregivers, as well as to the healthcare professionals, hospital staff, and clinical study coordinators for their invaluable support and dedication. Nicola Polverelli: Conceptualization; methodology; data curation; validation; supervision; writing—original draft; writing—review and editing. Annalisa Chiappella: Conceptualization; writing—original draft; writing—review and editing. Cristiana Carniti: Conceptualization; writing—original draft; writing—review and editing; formal analysis. Pierluigi Zinzani: Data curation. Maurizio Musso: Data curation. Maria Chiara Tisi: Data curation. Fabio Ciceri: Data curation. Ilaria Cutini: Data curation. Armando Santoro: Data curation. Patrizia Chiusolo: Data curation. Anna Maria Barbui: Data curation. Mirko Farina: Data curation. Livia Donzelli: Data curation. Lucia Brunello: Data curation. Massimo Martino: Data curation. Mauro Krampera: Data curation. Alessia Castellino: Data curation. Giovanni Grillo: Data curation. Barbara Botto: Data curation. Jacopo Olivieri: Data curation. Michele Clerico: Data curation. Pellegrino Musto: Data curation. Attilio Olivieri: Data curation. Antonio Bianchessi: Data curation. Irene Defrancesco: Data curation. Giulia Losi: Data curation. Caterina Zerbi: Data curation. Gianluca Martini: Data curation. Elisa Roncoroni: Data curation. Manuel Gotti: Data curation. Maria Grazia Benevento: Data curation. Alessia Taurino: Data curation. Anna Fedina: Data curation; project administration. Paolo Corradini: Conceptualization; writing—review and editing. Luca Arcaini: Methodology; conceptualization; writing—review and editing. N.P. received honoraria from Novartis and Kite Pharma and acted as a consultant for Kite Pharma. ACh advisory boards—AbbVie, Gilead-Sciences/Kite Pharma Inc., Incyte Corporation, and Sobi; lecture fees/educational events—Eli Lilly and Gilead-Sciences/Kite Pharma Inc. Other authors declare no conflict of interest. This study was approved by the ethics committee of the Fondazione IRCCS Istituto Nazionale dei Tumori (INT 180/19) and by the institutional review boards at each site (clinicaltrials gov. Identifier: NCT06339255). This research received no funding. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
CLINICAL OUTCOMES OF YOUNGER ADULT PATIENTS WITH PHILADELPHIANEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA, TREATED IN THE REAL-LIFE WITH A PEDIATRIC-LIKE REGIMEN BASED ON GIMEMA LAL1308 PROTOCOL: AN OBSERVATIONAL RETROSPECTIVE CAMPUS ALL STUDY Fabio Forghieri Haematologica, 2026 There is currently no definitive evidence that adolescents and young adults (AYA) with Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL) have poorer survival outcomes when receiving modern pediatric-inspired regimens (PIRs) compared with unmodified pediatric protocols. Moreover, major issues related to the application of full pediatric strategies to patients (pts) aged 18-40 years are the compliance to treatment and drug-related toxicity.We retrospectively recorded clinical data of 36 younger pts (median age 21 years, range 18-38) affected with Ph- ALL (28) or lymphoblastic lymphoma (LL) (8), who received a treatment inspired by the GIMEMA LAL1308 pediatric protocol (Testi et al, Am J Hematol 2021) in a multicenter real-life setting, across Italian centers partecipating to the Campus ALL network between 2014 and 2023, mainly investigating feasibility and efficacy of this intensive chemotherapeutic program.B- and T-cell immunophenotypes were observed in 23 (63.9%) and 13 (36.1%) ALL/LL cases, respectively. According to GIMEMA prognostic risk stratification based on laboratory and genetic features at diagnosis, 15 (53.6%), 6 (21.4%) and 7 (25%) ALL pts were classified as standard, high or very high risk, respectively. CNS localization at onset was detected in only 2 (5.6%) cases. Following induction course Ia, a morphologic CR was achieved in 24/28 (85.7%) ALL cases, while either a morphologic or radiologic/metabolic CR was eventually documented in 31/36 (86.1%) globally considered ALL/LL pts after phase Ib. Measurable residual disease (MRD) negativity by either molecular or flow-cytometry assays was reached in 17/23 (73.9%) evaluable ALL pts at the prognostic timepoint at the end of Ib induction cycle (TP2). Seven of 25 (28%) ALL pts in CR subsequently experienced either a morphologic or a MRD relapse, with 7 pts receiving blinatumonab, with or without previous salvage chemotherapy. Consolidation/maintenance approaches followed risk-adapted indications without dose-limiting complications, with 20 (55.6%) ALL/LL pts collectively receiving an allogeneic HSCT, due to either adverse prognostic factors, resistance to induction courses, morphologic relapse or MRD positivity at TP2 or subsequent determinations. At a median follow-up of 49 months (IQR 23-77), the median OS and DFS for the entire cohort were not reached, with 5-year OS and DFS of 76.4% and 69.1%, respectively. No significant differences in outcomes were recorded according to the ALL/LL diagnosis, B/T lineage, risk at diagnosis or, surprisingly, MRD status at TP2, probably due to the limited sample size or to optimal risk-adapted and MRD-driven intensification strategies, including prompt allocation to allogeneic HSCT. Unmodified pediatric regimens may be safely administered to AYA ALL pts in a real-life setting, with results that compare favorably to those of the LAL1308 trial or other intensive PIRs not yet incorporating modern frontline immunotherapeutic approaches.
Genomic profiling for decision-making in post–polycythemia vera and post–essential thrombocythemia myelofibrosis Barbara Mora, Francesca Palandri, Paola Guglielmelli, Andrew T. Kuykendall, Margherita Maffioli, Alessandra Iurlo, Valerio De Stefano, Silvia Salmoiraghi, Timothy Devos, Federico Itri, Francisco Cervantes, Jean-Jacques Kiladjian, Matteo G. Della Porta, Francesco Albano, Jason Gotlib, Giulia Benevolo, Marianna Caramella, Marco Ruggeri, Elisa Rumi, David M. Ross, Chiara Pessina, Ilaria Colugnat, Francesco Orsini, Giorgia Micucci, Giada Rotunno, Rami S. Komrokji, Daniele Cattaneo, Patrizia Chiusolo, Marta Bortolotti, Tiziano Barbui, Daniela Cilloni, Massimo Breccia, Giuseppe A Palumbo, Filippo Branzanti, Ludovica Margotto, Matteo Franchi, Alessandro M. Vannucchi, Francesco Passamonti Blood, 2026
Treatment of Acute Myeloid Leukemias and Myelodisplastic Syndromes Relapsing After Allogeneic Stem Cell Transplantation: An In-Depth Analysis of the GITMO AML/MDS-Relapse Registry Study Michele Malagola, Domenica Matranga, Luca Castagna, Daniele Avenoso, Vera Radici, Mirko Farina, Marco Galli, Eugenia Accorsi Buttini, Caterina Alati, Simona Bassi, Alessandra Biffi, Carlo Borghero, Alessandro Busca, Chiara Nozzoli, Angelo Michele Carella, Irene Maria Cavattoni, Raffaella Cerretti, Patrizia Chiusolo, Michele Cimminiello, Angela Cuoghi, Marco De Gobbi, Federico Vincenzo, Piero Galieni, Anna Paola Iori, Matteo Parma, Francesca Patriarca, Vincenzo Pavone, Alessandra Picardi, Eugenia Piras, Nicola Polverelli, Lucia Prezioso, Benedetta Rambaldi, Francesco Saraceni, Elvira Scalisi, Carmine Selleri, Cristina Skert, Alessandro Spina, Cristina Tecchio, Elena Oldani, Eliana Degrandi, Domenico Russo, Massimo Martino Clinical Lymphoma Myeloma and Leukemia, 2026
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis Anna Dodero, Giusy Ceparano, Beatrice Casadei, Piera Angelillo, Stefania Bramanti, Maria Chiara Tisi, Silva Ljevar, Federico Stella, Annalisa Chiappella, Barbara Botto, Ilaria Cutini, Giada Zanirato, Patrizia Chiusolo, Anna Maria Barbui, Mirko Farina, Alice Di Rocco, Giovanni Grillo, Jacopo Olivieri, Mauro Krampera, Marco Ladetto, Anna Guidetti, Pier Luigi Zinzani, Cristiana Carniti, Paolo Corradini Blood Advances, 2025
A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia Valeria Bica, Veronica Venafra, Giorgia Massacci, Simone Graziosi, Sara Gualdi, Gessica Minnella, Federica Sorà, Patrizia Chiusolo, Maria Elsa Brunetti, Gennaro Napolitano, Massimo Breccia, Dimitrios Mougiakakos, Martin Böttcher, Thomas Fischer, Livia Perfetto, Francesca Sacco Cell Communication and Signaling, 2025
PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey M. Turinetto, C. Marchetti, G. Scandurra, N. Colombo, G. Cormio, S. Cecere, D. Pellegrini, C. De Angelis, C. Abeni, M.C. Petrella, A. Ferrero, C. Camnasio, F. Villa, S. Mammoliti, M. Giordano, G. Valabrega, M. DeStefanis, G. Cirigliano, S. Boccia, M. Distefano, P. Chiusolo, M.T. Perri, V. Lombardo, G. Caruso, V. Loizzi, E. Coppola, V. Barberi, M.R. Lamia, A. Fagotti, S. Pignata ESMO Open, 2025
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia(Blood Cancer Journal, 10.1038/s41408-025-01394-7) Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi, Patrizia Chiusolo, Carla Filì, Carola Riva, Valeria Cardinali, Marinunzia Franciosa, Federica Pilo, Raffaele Palmieri, Lorenzo Esposito, Diego Menotti, Salvatore Perrone, Antonino Mulè, Caterina Alati, Ernesto Vigna, Michela Dargenio, Giulia De Luca, Alessandra Sperotto, Ilaria Tanasi, Cristina Papayannidis, Matteo Molica, Paola Minetto, Giorgia Battipaglia, Mara Memoli, Prassede Salutari, Lorenzo Brunetti, Elisabetta Todisco, Ivana Lotesoriere, Alessandro Isidori, Giuseppe Alberto Palumbo, Mario Annunziata, Michele Gottardi, Massimo Gentile, Maria Paola Martelli, Debora Capelli, Massimo Martino, Marco Rossi, Felicetto Ferrara, Adriano Venditti, Claudio Romani, Sara Galimberti, Anna Candoni, Luana Fianchi, Livio Pagano, Giovanni Marconi, Roberto Massimo Lemoli, Francesco Di Raimondo, Atto Billio, Fanny Erika Palumbo, Fabrizio Pane, Andrea Duminuco, Fabio Guolo Blood Cancer Journal, 2025
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia Calogero Vetro, Bruno Garibaldi, Francesco Grimaldi, Patrizia Chiusolo, Carla Filì, Carola Riva, Valeria Cardinali, Marinunzia Franciosa, Federica Pilo, Raffaele Palmieri, Lorenzo Esposito, Diego Menotti, Salvatore Perrone, Antonino Mulè, Caterina Alati, Ernesto Vigna, Michela Dargenio, De De Luca, Alessandra Sperotto, Ilaria Tanasi, Cristina Papayannidis, Matteo Molica, Paola Minetto, Giorgia Battipaglia, Mara Memoli, Prassede Salutari, Lorenzo Brunetti, Elisabetta Todisco, Ivana Lotesoriere, Alessandro Isidori, Giuseppe Alberto Palumbo, Mario Annunziata, Michele Gottardi, Massimo Gentile, Maria Paola Martelli, Debora Capelli, Massimo Martino, Marco Rossi, Felicetto Ferrara, Adriano Venditti, Claudio Romani, Sara Galimberti, Anna Candoni, Luana Fianchi, Livio Pagano, Giovanni Marconi, Roberto Massimo Lemoli, Francesco Di Raimondo, Atto Billio, Fanny Erika Palumbo, Fabrizio Pane, Andrea Duminuco, Fabio Guolo Blood Cancer Journal, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation Fabio Guolo, Luana Fianchi, Maria Paola Martelli, Federico Lussana, Francesco Grimaldi, Federica Pilo, Michela Rondoni, Carla Filì, Paola Minetto, Debora Capelli, Patrizia Chiusolo, Massimo Breccia, Sara Mastaglio, Massimo Bernardi, Monica Bocchia, Monica Fumagalli, Sara Galimberti, Valentina Mancini, Anna Lisa Piccioni, Luca Maurillo, Nicola Stefano Fracchiolla, Raffaele Palmieri, Calogero Vetro, Cristina Papayannidis, Lorenzo Brunetti, Alessandra Sperotto, Federica Gigli, Patrizia Zappasodi, Antonino Mulé, Caterina Patti, Erika Borlenghi, Michelina Dargenio, Federica Lessi, Marco Cerrano, Daniela Cilloni, Alessandro Isidori, Monia Lunghi, Caterina Alati, Carmela Gurrieri, Carola Riva, Giovanni Marconi, Ivana Lotesoriere, Samuele Gatani, Anna Maria Scattolin, Manuela Caizzi, Salvatore Perrone, Atto Billio, Filippo Gherlinzoni, Francesco Mannelli, Michele Gottardi, Roberto Cairoli, Anna Candoni, Felicetto Ferrara, Livio Pagano, Roberto Massimo Lemoli, Adriano Venditti, Elisabetta Todisco American Journal of Hematology, 2025
Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 study Renato Bassan, Sabina Chiaretti, Irene Della Starza, Alessandra Santoro, Orietta Spinelli, Manuela Tosi, Loredana Elia, Deborah Cardinali, Maria Stefania De Propris, Matteo Piccini, Federico Lussana, Mario Annunziata, Patrizia Chiusolo, Patrizia Zappasodi, Erika Borlenghi, Matteo Leoncin, Catello Califano, Monica Bocchia, Francesco Di Raimondo, Francesco Grimaldi, Mario Tiribelli, Anna Candoni, Albana Lico, Ernesta Audisio, Monia Lunghi, Anna Maria Mianulli, Mariangela Di Trani, Valentina Arena, Monica Messina, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà Blood, 2025
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study Mirko Farina, Simona Bernardi, Michele Malagola, Alessandro Re, Eugenio Galli, Marcello Riva, Ilaria Cutini, Alessandro Leoni, Massimo Martino, Silvia Ferrari, Giorgia Battipaglia, Mattia Novo, Maurizio Musso, Giovanni Grillo, Stella Santarone, Mauro Krampera, Andrea Aroldi, Nicola Polverelli, Luca Arcaini, Besjana Xhahysa, Daniele Avenoso, Maria Chiara Tisi, Patrizia Chiusolo, Domenico Russo Bone Marrow Transplantation, 2025
Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study Luana Fianchi, Alfonso Piciocchi, Fabio Guolo, Francesco Marchesi, Giovanni Marsili, Chiara Cattaneo, Michele Gottardi, Francesco Restuccia, Anna Candoni, Elettra Ortu La Barbera, Rita Fazzi, Crescenza Pasciolla, Olimpia Finizio, Nicola Fracchiolla, Mario Delia, Federica Lessi, Michela Dargenio, Valentina Bonuomo, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Picardi, Claudia Basilico, Monica Piedimonte, Paola Minetto, Patrizia Chiusolo, Lucia Prezioso, Caterina Buquicchio, Lorella Melillo, Daniele Zama, Francesca Farina, Valentina Mancini, Michela Rondoni, Alessandro Busca, Livio Pagano Annals of Hematology, 2025
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial Anna Maria Raiola, Benedetto Bruno, Antonio Maria Risitano, Federico Mosna, Irene Maria Cavattoni, Francesco Onida, Giorgia Saporiti, Francesca Patriarca, Marta Lisa Battista, Vincenzo Pavone, Anna Mele, Patrizia Chiusolo, Simona Sica, Barbara Loteta, Carmen di Grazia, Angelo Michele Carella, Dalila Salvatore, Enrico Morello, Alessandro Leoni, Luisa Giaccone, Paolo Bernasconi, Elisabetta Terruzzi, Nicola Mordini, Carlo Borghero, Francesco Zallio, Mario Luppi, Anna Grassi, Attilio Olivieri, Eugenia Piras, Nicoletta Sacchi, Giovannino Ciccone, Anna Castiglione, Eliana Degrandi, Emanuele Angelucci, Massimo Martino, Francesca Bonifazi Blood Advances, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study Federico Stella, Martina Pennisi, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria Chiara Tisi, Piera Angelillo, Ilaria Cutini, Massimo Martino, Angelica Barone, Francesca Bonifazi, Armando Santoro, Federica Sorà, Mattia Novo, Anna Maria Barbui, Domenico Russo, Maurizio Musso, Giovanni Grillo, Mauro Krampera, Jacopo Olivieri, Lucia Brunello, Federica Cavallo, Massimo Massaia, Luca Arcaini, Lucia Farina, Pierluigi Zinzani, Rosalba Miceli, Paolo Corradini Transplantation and Cellular Therapy, 2025
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT U. La Rocca, Roberto Ricci, A. Piciocchi, W. Barberi, E. Oldani, A. Dominietto, R. Cerretti, Alessandra Picardi, Francesca Bonifazi, Riccardo Saccardi, M. Faraci, Giovanni Grillo, Lucia Farina, Benedetto Bruno, A. Grassi, A. Proia, Elena Tagliaferri, Giuseppina de Simone, M. Malagola, M. Cerno, Simone Cesaro, Paolo Bernasconi, L. Prezioso, P. Carluccio, N. Mordini, Matteo Pelosini, A. Olivieri, Patrizia Chiusolo, S. Santarone, M. Cimminiello, Roberto Crocchiolo, Franco Papola, G. Rombolà, N. Sacchi, Valeria Miotti, Lia Mele, B. Mazzi, F. Ciceri, Massimo Martino, A. P. Iori Blood Transfusion, 2025
Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation Chiara Nozzoli, Martina Pucillo, Luisa Giaccone, Alessandro Rambaldi, Maria Teresa Lupo Stanghellini, Edoardo Benedetti, Domenico Russo, Nicola Mordini, Silvia Mangiacavalli, Paolo Bernasconi, Matteo Parma, Paola Carluccio, Piero Galieni, Paolo Rivela, Massimo Martino, Patrizia Chiusolo, Miriam Isola, Maria De Martino, Elena Oldani, Eliana Degrandi, Riccardo Boncompagni, Elisabetta Antonioli, Fabrizio Carnevale, Monica Tozzi, Carmine Selleri, Renato Fanin, Francesca Patriarca Transplantation and Cellular Therapy, 2025
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey) Michele Malagola, Luca Castagna, Mirko Farina, Simone Pellizzeri, Eliana Degrandi, Elena Oldani, Simona Bassi, Giorgia Battipaglia, Carlo Borghero, Lucia Brunello, Alessandro Busca, Raffaella Ceretti, Patrizia Chiusolo, Michele Cimminiello, Vincenzo Federico, Camilla Frieri, Piero Galieni, Sara Galimberti, Andrea Gilioli, Annalisa Imovilli, Walter Barbieri, Chiara Nozzoli, Alessandra Picardi, Eugenia Piras, Nicola Polverelli, Lucia Prezioso, Stella Santarone, Renato Scalone, Ilaria Scortechini, Bianca Serio, Cristina Skert, Alessandro Spina, Elisabetta Terruzzi, Massimo Martino Leukemia and Lymphoma, 2025
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study Davide Lazzarotto, Marco Cerrano, Cristina Papayannidis, Sabina Chiaretti, Federico Mosna, Nicola Fracchiolla, Patrizia Zappasodi, Silvia Imbergamo, Maria Ilaria Del Principe, Monia Lunghi, Federico Lussana, Matteo Piccini, Monica Fumagalli, Michelina Dargenio, Prassede Salutari, Fabio Forghieri, Teresa Giulia Da Molin, Massimiliano Bonifacio, Matteo Olivi, Fabio Giglio, Silvia Trappolini, Matteo Leoncin, Antonino Mule, Mario Delia, Crescenza Pasciolla, Francesco Grimaldi, Benedetta Cambo, Lidia Santoro, Fabio Guolo, Paola Minetto, Marzia Defina, Patrizia Chiusolo, Matteo Fanin, Endri Mauro, Lara Aprile, Carla Mazzone, Fabio Trastulli, Maria Ciccone, Marco De Gobbi, Alessandro Cignetti, Eleonora De Bellis, Valentina Mancini, Alfonso Piciocchi, Marco Vignetti, Giovanni Marsili, Irene Della Starza, Renato Fanin, Mario Luppi, Felicetto Ferrara, Giovanni Pizzolo, Renato Bassan, Robin Foa, Anna Candoni Haematologica, 2025
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial Gianluca Cavallaro, Anna Grassi, Chiara Pavoni, Maria Caterina Micò, Alessandro Busca, Irene Maria Cavattoni, Stella Santarone, Carlo Borghero, Attilio Olivieri, Giuseppe Milone, Patrizia Chiusolo, Pellegrino Musto, Riccardo Saccardi, Francesca Patriarca, Fabrizio Pane, Giorgia Saporiti, Paolo Rivela, Elisabetta Terruzzi, Raffaella Cerretti, Giuseppe Marotta, Angelo Michele Carella, Arnon Nagler, Domenico Russo, Paolo Corradini, Paolo Bernasconi, Anna Paola Iori, Luca Castagna, Nicola Mordini, Elena Oldani, Carmen Di Grazia, Andrea Bacigalupo, Alessandro Rambaldi Blood Cancer Journal, 2024
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Patrizia Chiusolo, Alice Di Rocco, Maria C. Tisi, Matteo G. Carrabba, Ilaria Cutini, Massimo Martino, Anna Dodero, Francesca Bonifazi, Armando Santoro, Federica Sorà, Barbara Botto, Anna M. Barbui, Domenico Russo, Maurizio Musso, Giovanni Grillo, Mauro Krampera, Jacopo Olivieri, Marco Ladetto, Federica Cavallo, Massimo Massaia, Luca Arcaini, Martina Pennisi, Pier L. Zinzani, Rosalba Miceli, Paolo Corradini Blood Cancer Discovery, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Alessia Campagna, , Victor Savevski, Armando Santoro, Najla Al Ali, David Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Nicolaus Kroger, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami Komrokji, Francesca Ieva, Matteo Giovanni Della Porta, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz Beyá, Andrés Jerez, Francisca Hernández, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Anne-Sophie Kubasch, Andrea Bacigalupo, Anna Maria Raiola, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri Journal of Clinical Oncology, 2024
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study Annalisa Chiappella, Beatrice Casadei, Patrizia Chiusolo, Alice Di Rocco, Silva Ljevar, Martina Magni, Piera Angelillo, Anna Maria Barbui, Ilaria Cutini, Anna Dodero, Francesca Bonifazi, Maria Chiara Tisi, Stefania Bramanti, Maurizio Musso, Mirko Farina, Massimo Martino, Mattia Novo, Giovanni Grillo, Francesca Patriarca, Giulia Zacchi, Mauro Krampera, Martina Pennisi, Eugenio Galli, Maurizio Martelli, Andrés J. M. Ferreri, Silvia Ferrari, Riccardo Saccardi, Anisa Bermema, Anna Guidetti, Rosalba Miceli, Pier Luigi Zinzani, Paolo Corradini Leukemia, 2024
Haploidentical bone marrow transplantation for AML in remission after TBF conditioning: a long-term follow-up Anna M. Raiola, Carmen Di Grazia, Alida Dominietto, Stefania Bregante, Sabrina Giammarco, Riccardo Varaldo, Federica Sorà, Elisabetta Metafuni, Maria A. Limongiello, Antonella Laudisi, Monica Passannante, Eugenio Galli, Massimiliano Gambella, Simona Sica, Andrea Bacigalupo, Emanuele Angelucci, Patrizia Chiusolo Blood Advances, 2024
ECP versus ruxolitinib in steroid-refractory chronic GVHD – a retrospective study by the EBMT transplant complications working party Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, H. Christian Reinhardt, Ksenia Afanasyeva, Daniele Avenoso, Tobias A. W. Holderried, Brian Thomas Kornblit, Eleni Gavriilaki, Carmen Martinez, Patrizia Chiusolo, Maria Caterina Mico, Elisabeth Dagunet, Stina Wichert, Hakan Ozdogu, Agnieszka Piekarska, Francesca Kinsella, Grzegorz W. Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric Bone Marrow Transplantation, 2024
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study Francesco Malfona, Ilaria Tanasi, Matteo Piccini, Cristina Papayannidis, Vincenzo Federico, Valentina Mancini, Elisa Roncoroni, Elisabetta Todisco, Simona Bianchi, Giulia Ciotti, Patrizia Chiusolo, Massimo Gentile, Valentina Gianfelici, Fabio Giglio, Michele Malagola, Antonino Mulé, Francesco Saraceni, Calogero Vetro, Francesco Zallio, Luca Vincenzo Cappelli, Giovanni Pizzolo, Robin Foà, Massimiliano Bonifacio, Sabina Chiaretti Haematologica, 2024
CAR-T Cell Therapy for T-Cell Malignancies Ugo Testa, Patrizia Chiusolo, Elvira Pelosi, Germana Castelli, Giuseppe Leone Mediterranean Journal of Hematology and Infectious Diseases, 2024
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT Juan Carlos Hernández-Boluda, Diderik-Jan Eikema, Linda Koster, Nicolaus Kröger, Marie Robin, Moniek de Witte, Jürgen Finke, Maria Chiara Finazzi, Annoek Broers, Ludek Raida, Nicolaas Schaap, Patrizia Chiusolo, Mareike Verbeek, Carin L. E. Hazenberg, Kazimierz Halaburda, Aleksandr Kulagin, Hélène Labussière-Wallet, Tobias Gedde-Dahl, Werner Rabitsch, Kavita Raj, Joanna Drozd-Sokolowska, Giorgia Battipaglia, Nicola Polverelli, Tomasz Czerw, Ibrahim Yakoub-Agha, Donal P. McLornan Bone Marrow Transplantation, 2023
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in “Real-Life”: The SEIFEM Experience Luana Fianchi, Fabio Guolo, Francesco Marchesi, Chiara Cattaneo, Michele Gottardi, Francesco Restuccia, Anna Candoni, Elettra Ortu La Barbera, Rita Fazzi, Crescenza Pasciolla, Olimpia Finizio, Nicola Fracchiolla, Mario Delia, Federica Lessi, Michelina Dargenio, Valentina Bonuomo, Maria Ilaria Del Principe, Patrizia Zappasodi, Marco Picardi, Claudia Basilico, Monica Piedimonte, Paola Minetto, Antonio Giordano, Patrizia Chiusolo, Lucia Prezioso, Caterina Buquicchio, Lorella Maria Antonia Melillo, Daniele Zama, Francesca Farina, Valentina Mancini, Irene Terrenato, Michela Rondoni, Irene Urbino, Mario Tumbarello, Alessandro Busca, Livio Pagano Cancers, 2023
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo’ Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta Journal of Clinical Oncology, 2023
Acute graft versus host disease 1976–2020: reduced incidence and predictive factors Alessandra Di Francesco, Anna Maria Raiola, Alida Dominietto, Carmen Di Grazia, Francesca Gualandi, Maria Teresa Van Lint, Stefania Bregante, Patrizia Chiusolo, Luca Laurenti, Federica Sora, Sabrina Giammarco, Elisabetta Metafuni, Alberto Fresa, Simona Sica, Emanuele Angelucci, Andrea Bacigalupo Frontiers in Medicine, 2023
Donor cell-derived myelofibrosis relapse after allogeneic stem cell transplantation Patrizia Chiusolo, Nicoletta Orlando, Sabrina Giammarco, Monica Rossi, Elisabetta Metafuni, Salvatore Leotta, Giuseppe Milone, Caterina Giovanna Valentini, Maria Bianchi, Filippo Frioni, Claudio Pellegrino, Federica Sorà, Luigi Maria Larocca, Simona Sica, Andrea Bacigalupo, Luciana Teofili Haematologica, 2023
ECP versus ruxolitinib in steroid-refractory acute GVHD – a retrospective study by the EBMT transplant complications working party Olaf Penack, Christophe Peczynski, William Boreland, Jessica Lemaitre, Ksenia Afanasyeva, Brian Kornblit, Manuel Jurado, Carmen Martinez, Annalisa Natale, Jose Antonio Pérez-Simón, Lucia Brunello, Daniele Avenoso, Stefan Klein, Zubeyde Nur Ozkurt, Concha Herrera, Stina Wichert, Patrizia Chiusolo, Eleni Gavriilaki, Grzegorz W. Basak, Hélène Schoemans, Christian Koenecke, Ivan Moiseev, Zinaida Peric Frontiers in Immunology, 2023
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer Patrizia Chiusolo, Claudia Marchetti, Monica Rossi, Gessica Minnella, Vanda Salutari, Mariagrazia Distefano, Sabrina Giammarco, Elisabetta Metafuni, Angelo Minucci, Filippo Frioni, Cristiana Gasbarrino, Maria Colangelo, Daniela Orteschi, Anna Fagotti, Domenica Lorusso, Livio Pagano, Valerio De Stefano, Giovanni Scambia, Simona Sica American Journal of Hematology, 2022
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report Sabina Chiaretti, Massimiliano Bonifacio, Roberta Agrippino, Fabio Giglio, Mario Annunziata, Antonio Curti, Maria Ilaria Del Principe, Prassede Salutari, Mariarita Sciumè, Mario Delia, Marco Armenio, Valentina Mancini, Antonino Mulè, Francesco Grimaldi, Giovanna Rege-Cambrin, Lidia Santoro, Federico Lussana, Patrizia Chiusolo, Crescenza Pasciolla, Anna Maria Scattolin, Marco Cerrano, Maria Ciccone, Marzia Defina, Fabio Forghieri, Carla Mazzone, Matteo Piccini, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà Haematologica, 2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01 Francesca Bonifazi, Chiara Pavoni, Jacopo Peccatori, Fabio Giglio, Mario Arpinati, Alessandro Busca, Paolo Bernasconi, Anna Grassi, Anna Paola Iori, Francesca Patriarca, Lucia Brunello, Carmen Di Grazia, Angelo Michele Carella, Daniela Cilloni, Alessandra Picardi, Anna Proia, Stella Santarone, Roberto Sorasio, Paola Carluccio, Patrizia Chiusolo, Alessandra Cupri, Mario Luppi, Chiara Nozzoli, Donatella Baronciani, Marco Casini, Giovanni Grillo, Maurizio Musso, Francesco Onida, Giulia Palazzo, Matteo Parma, Stefania Tringali, Adriana Vacca, Daniele Vallisa, Nicoletta Sacchi, Elena Oldani, Arianna Masciulli, Angela Gheorghiu, Corrado Girmenia, Massimo Martino, Benedetto Bruno, Alessandro Rambaldi, Fabio Ciceri, and Bone Marrow Transplantation, 2022
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study Marco Cerrano, Massimiliano Bonifacio, Matteo Olivi, Antonio Curti, Michele Malagola, Michelina Dargenio, Anna Maria Scattolin, Cristina Papayannidis, Fabio Forghieri, Carmela Gurrieri, Ilaria Tanasi, Patrizia Zappasodi, Roberta La Starza, Nicola Stefano Fracchiolla, Patrizia Chiusolo, Luisa Giaccone, Maria Ilaria Del Principe, Fabio Giglio, Marzia Defina, Claudio Favre, Carmelo Rizzari, Barbara Castella, Giovanni Pizzolo, Felicetto Ferrara, Sabina Chiaretti, Robin Foà Haematologica, 2022
Use of DPB1 T-cell epitope algorithm among italian transplant centers: A survey on behalf of Associazione Italiana di Immunogenetica e Biologia dei Trapianti Roberto Crocchiolo, Lia Mele, Manuela Testi, Mariadele Scollo Chiara, Barbara Murgia, Angela Rossi, Cinzia Vecchiato, Paola Grammatico, Donata Mininni, Elena Longhi, Silvia Manfroi, Silvia Giuliodori, Laura Castellani, Graziella Carella, Sara Lai, Pia Azzaro Maria, Benedetta Mazzi, Laura Perotti, Roberta Penta, Claudia Lombardo, Rita Tognellini, Marco Andreani, Paola Albergoni Maria, Sonia Nesci, Valentina Cappuzzo, Patrizia Chiusolo, Elena Garino, Giuseppe Cappucci, Nadia Ceschini, Elena Bevilacqua, Elisabetta Guizzardi, Marina Tagliaferri Cinzia, Antonina Piazza, Carlo Carcassi, Valeria Miotti Hla, 2021
Second haploidentical stem cell transplantation for primary graft failure Sabrina Giammarco, Anna Maria Raiola, Carmen Di Grazia, Stefania Bregante, Francesca Gualandi, Riccardo Varaldo, Patrizia Chiusolo, Federica Sora, Simona Sica, Luca Laurenti, Elisabetta Metafuni, Idanna Innocenti, Francesco Autore, Barbara Murgia, Andrea Bacigalupo, Emanuele Angelucci Bone Marrow Transplantation, 2021
Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021 Andrea Bacigalupo, Idanna Innocenti, Elena Rossi, Federica Sora, Eugenio Galli, Francesco Autore, Elisabetta Metafuni, Patrizia Chiusolo, Sabrina Giammarco, Luca Laurenti, Giulia Benintende, Simona Sica, Valerio De Stefano Frontiers in Immunology, 2021
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen Patrizia Chiusolo, Stefania Bregante, Sabrina Giammarco, Teresa Lamparelli, Lucia Casarino, Alida Dominietto, Anna Maria Raiola, Elisabetta Metafuni, Carmen Di Grazia, Francesca Gualandi, Federica Sora, Luca Laurenti, Simona Sica, Gianni Barosi, Fabio Guolo, Monica Rossi, Elena Rossi, Alessandro Vannucchi, Alessio Signori, Valerio De Stefano, Andrea Bacigalupo, Emanuele Angelucci American Journal of Hematology, 2021
Increased CD95 (Fas) and PD-1 expression in peripheral blood T lymphocytes in COVID-19 patients Silvia Bellesi, Elisabetta Metafuni, Stefan Hohaus, Elena Maiolo, Federica Marchionni, Simone D’Innocenzo, Marilena La Sorda, Manuela Ferraironi, Francesco Ramundo, Massimo Fantoni, Rita Murri, Antonella Cingolani, Simona Sica, Antonio Gasbarrini, Maurizio Sanguinetti, Patrizia Chiusolo, Valerio De Stefano British Journal of Haematology, 2020
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy Jacopo Mariotti, Anna Maria Raiola, Andrea Evangelista, Angelo Michele Carella, Massimo Martino, Francesca Patriarca, Antonio Risitano, Stefania Bramanti, Alessandro Busca, Luisa Giaccone, Lucia Brunello, Emanuela Merla, Lucia Savino, Barbara Loteta, Giuseppe Console, Renato Fanin, Alessandra Sperotto, Luana Marano, Serena Marotta, Camilla Frieri, Simona Sica, Patrizia Chiusolo, Samia Harbi, Sabine Furst, Armando Santoro, Andrea Bacigalupo, Didier Blaise, Emanuele Angelucci, Domenico Mavilio, Luca Castagna, Benedetto Bruno Blood Advances, 2020
Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody—Begelomab Andrea Bacigalupo, Emanuele Angelucci, Anna Maria Raiola, Riccardo Varaldo, Carmen Di Grazia, Francesca Gualandi, Edoardo Benedetti, Antonio Risitano, Maurizio Musso, Francesco Zallio, Fabio Ciceri, Patrizia Chiusolo, Simona Sica, Alessandro Rambaldi, Francesca Bonifazi, Matteo Parma, Massimo Martino, Francesco Onida, Anna Paola Iori, Carmine Selleri, Carlo Borghero, Alice Bertaina, Lucia Prezioso, Mattia Algeri, Franco Locatelli Bone Marrow Transplantation, 2020
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study Frédéric Baron, Fabio Efficace, Laura Cannella, Petra Muus, Silvia Trisolini, Constantijn J. M. Halkes, Paola Fazi, Marco Vignetti, Jean‐Pierre Marie, Patrizia Chiusolo, Walter van der Velden, Edoardo La Sala, Umberto Vitolo, Xavier Thomas, Francois Lefrère, Francesco Di Raimondo, Jean‐Henri Bourhis, Giorgina Specchia, José E. Guimarães, Bernardino Allione, Radovan Vrhovac, Felicetto Ferrara, Marian Stevens‐Kroef, Liv Meert, Theo de Witte, Roelof Willemze, Sergio Amadori, Stefan Suciu American Journal of Hematology, 2020
A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi Jacopo Olivieri, Federico Mosna, Matteo Pelosini, Angelo Fama, Sara Rattotti, Margherita Giannoccaro, Giuseppe Carli, Maria Chiara Tisi, Simone Ferrero, Nicola Sgherza, Anna Maria Mazzone, Dario Marino, Teresa Calimeri, Giacomo Loseto, Francesco Saraceni, Gabriella Tomei, Simona Sica, Giulia Perali, Katia Codeluppi, Atto Billio, Attilio Olivieri, Enrico Orciuolo, Rossella Matera, Piero Maria Stefani, Carlo Borghero, Paola Ghione, Nicola Cascavilla, Francesco Lanza, Patrizia Chiusolo, Silvia Finotto, Irene Federici, Filippo Gherlinzoni, Riccardo Centurioni, Renato Fanin, Francesco Zaja Biology of Blood and Marrow Transplantation, 2018
The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future Tessa M. Andermann, Jonathan U. Peled, Christine Ho, Pavan Reddy, Marcie Riches, Rainer Storb, Takanori Teshima, Marcel R.M. van den Brink, Amin Alousi, Sophia Balderman, Patrizia Chiusolo, William B. Clark, Ernst Holler, Alan Howard, Leslie S. Kean, Andrew Y. Koh, Philip L. McCarthy, John M. McCarty, Mohamad Mohty, Ryotaro Nakamura, Katy Rezvani, Brahm H. Segal, Bronwen E. Shaw, Elizabeth J. Shpall, Anthony D. Sung, Daniela Weber, Jennifer Whangbo, John R. Wingard, William A. Wood, Miguel-Angel Perales, Robert R. Jenq, Ami S. Bhatt Biology of Blood and Marrow Transplantation, 2018
Steroid treatment of acute graft-versus-host disease grade I: A randomized trial Andrea Bacigalupo, Giuseppe Milone, Alessandra Cupri, Antonio Severino, Franca Fagioli, Massimo Berger, Stella Santarone, Patrizia Chiusolo, Simona Sica, Sonia Mammoliti, Roberto Sorasio, Daniela Massi, Maria Teresa Van Lint, Anna Maria Raiola, Francesca Gualandi, Carmine Selleri, Maria Pia Sormani, Alessio Signori, Antonio Risitano, Francesca Bonifazi Haematologica, 2017
Changes in protein serum levels during stem cell transplantation Elisabetta Metafuni, Sabrina Giammarco, Daniela Giovanna De Ritis, Monica Rossi, Francesco Corrente, Nicola Piccirillo, Andrea Paolo Bacigalupo, Simona Sica, Patrizia Chiusolo European Journal of Clinical Investigation, 2017
Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: A nationwide retrospective survey from Italy C Girmenia, G M Rossolini, A Piciocchi, A Bertaina, G Pisapia, D Pastore, S Sica, A Severino, L Cudillo, F Ciceri, R Scimè, L Lombardini, C Viscoli, A Rambaldi, the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Marco Frigeni, Alessandro Rambaldi, Consuelo Corti, Fabio Ciceri, Gabriella Mometto, Claudio Annaloro, Erminia Casari, Luca Castagna, Giuseppe Rossi, Chiara Cattaneo, Domenico Russo, Valeria Cancelli, Emilio Paolo Alessandrino, Francesco Ripamonti, Fabio Pavan, Attilio Rovelli, Clara Pecoraro, Alessandro Busca, Francesca Carraro, Franca Fagioli, Susanna Gallo, Daniele Caravelli, Marco De Gobbi, Giuseppe Saglio, Claudia Castellino, Nicola Mordini, Gianluca Gaidano, Luca Nassi, Roberto Raimondi, Michele Vespignani, Anna Maria Scattolin, Irene Sara Panizzolo, Simone Cesaro, Anna Candoni, Francesca Patriarca, Andrea Bacigalupo, Annamaria Raiola, Elio Castagnola, Edoardo Lanino, Marta Stanzani, Giuseppe Bandini, Erika Massaccesi, Arcangelo Prete, Simona Bassi, Daniele Vallisa, Cecilia Caramatti, Franco Aversa, Eliana Zuffa, Stefano Guidi, Alberto Bosi, Veronica Tintori, Anna Paola Iori, Saveria Capria, Laura Cudillo, William Arcese, Teresa Dentamaro, Paolo De Fabritiis, Barbara Anaclerico, Anna Chierichini, Monica Piedimonte, Antonella Ferrari, Francesco Marchesi, Andrea Mengarelli, Elisabetta Cerchiara, Maria Cristina Tirindelli, Javid Gaziev, Alessandro Severino, Ignazio Majolino, Patrizia Chiusolo, Simona Sica, Alice Bertaina, Barbarella Lucarelli, Maria Speranza Massei, Alessandra Carotti, Katia Perruccio, Maurizio Caniglia, Stella Santarone, Paolo Di Bartolomeo, Serena Mazzotta, Piero Galieni, Attilio Olivieri, Gennaro De Rosa, Antonio Risitano, Mario Delia, Giorgina Specchia, Giulia Palazzo, Giovanni Pisapia, Giuseppe Messina, Giuseppe Irrera, Emanuele Angelucci, Donatella Baronciani, Adriana Vacca, Alessandra Crescimanno, Maurizio Musso, Rosanna Scimè, Alida Imbriani, Giuseppe Milone Bone Marrow Transplantation, 2015
Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: A prospective study of the gruppo italiano trapianto midollo osseo (GITMO) Corrado Girmenia, Anna Maria Raiola, Alfonso Piciocchi, Alessandra Algarotti, Marta Stanzani, Laura Cudillo, Clara Pecoraro, Stefano Guidi, Anna Paola Iori, Barbara Montante, Patrizia Chiusolo, Edoardo Lanino, Angelo Michele Carella, Elisa Zucchetti, Benedetto Bruno, Giuseppe Irrera, Francesca Patriarca, Donatella Baronciani, Maurizio Musso, Arcangelo Prete, Antonio Maria Risitano, Domenico Russo, Nicola Mordini, Domenico Pastore, Adriana Vacca, Francesco Onida, Sadia Falcioni, Giovanni Pisapia, Giuseppe Milone, Daniele Vallisa, Attilio Olivieri, Alessandro Bonini, Elio Castagnola, Simona Sica, Ignazio Majolino, Alberto Bosi, Alessandro Busca, William Arcese, Giuseppe Bandini, Andrea Bacigalupo, Alessandro Rambaldi, Anna Locasciulli Biology of Blood and Marrow Transplantation, 2014
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome Emilio Paolo Alessandrino, Matteo G. Della Porta, Luca Malcovati, Christopher H Jackson, Cristiana Pascutto, Andrea Bacigalupo, Maria Teresa van Lint, Michele Falda, Massimo Bernardi, Francesco Onida, Stefano Guidi, Anna Paola Iori, Raffaella Cerretti, Paola Marenco, Pietro Pioltelli, Emanuele Angelucci, Rosi Oneto, Francesco Ripamonti, Alessandro Rambaldi, Alberto Bosi, Mario Cazzola, Gruppo Italiano Trapianto di Midollo Osseo (GITMO) American Journal of Hematology, 2013
Antituberculosis therapy and imatinib for chronic myeloid leukemia. Clinical Infectious Diseases an Official Publication of the Infectious Diseases Society of America, 2006
Hormonal replacement therapy after stem cell transplantation Paola Piccioni, Paolo Scirpa, Ilenia D’Emilio, Federica Sora, Marilisa Scarciglia, Luca Laurenti, Silvia De Matteis, Simona Sica, Giuseppe Leone, Patrizia Chiusolo Maturitas, 2004
Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir Haematologica, 2004
Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population Haematologica, 2004
Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies Haematologica, 2002
Fatal bone marrow aplasia during interferon-α treatment in chronic myelogenous leukemia Haematologica, 2000
Near-tetraploid acute myeloid leukemia after allogenic bone marrow transplantation Haematologica, 2000
Lymphoid blastic crisis in Philadelphia chromosome-positive chronic granulocytic leukemia following high-grade non-Hodgkins lymphoma. A case report and review of literature Haematologica, 2000
Immunologic short term reconstitution after tandem unselected peripheral blood progenitor cell transplantation for multiple myeloma Haematologica, 2000
Long-term immune recovery after CD34+ immunoselected and unselected peripheral blood progenitor cell transplantation: A case-control study Haematologica, 1999
Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation Bone Marrow Transplantation, 1995
